Phage Therapy for Pseudomonas aeruginosa Lung Infections: A Review
Open Access
- 1 December 2025
- journal article
- review article
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 19 (4) , 2415-2428
Abstract
Pseudomonas aeruginosa is a leading cause of persistent and severe lung infections, especially in individuals with weakened immune systems and those suffering from conditions like cystic fibrosis or bronchiectasis. The pathogen’s resistance to antibiotics, driven by its ability to form biofilms, activate efflux pumps, and produce enzymes that break down drugs, has significantly limited the effectiveness of standard antimicrobial therapies. This review explores the increasing promise of bacteriophage therapy as both an alternative and a complementary approach for addressing multidrug-resistant (MDR) P. aeruginosa infections in the lungs. Phages, viruses that specifically target bacteria, offer strain-specific bactericidal activity, often bypassing mechanisms of antibiotic resistance. Recent studies demonstrate that phage monotherapy and phage-antibiotic combinations can effectively disrupt biofilms and enhance bacterial clearance, particularly when phage cocktails or targeted delivery systems are employed. Additionally, the review explores delivery routes for pulmonary infections and the formulation challenges that affect phage stability and bioavailability. Clinical cases and ongoing trials further underscore the feasibility and safety of phage therapy in real-world applications. However, hurdles such as phage immunogenicity, rapid clearance, and regulatory limitations must be addressed before widespread clinical implementation. Overall, phage therapy holds significant promise in overcoming the therapeutic stagnation posed by MDR P. aeruginosa, especially in chronic and nosocomial lung infections, and warrants continued research and clinical validation.Keywords
This publication has 98 references indexed in Scilit:
- The Hydrophobic Stabilization of Pseudomonas aeruginosa Bacteriophage F8 and the Influence of Modified Bacteriophage Preparation on Biofilm DegradationCurrent Microbiology, 2024
- Bacteriophage Control of Infectious Biofilms2023
- A novel lytic phage exhibiting a remarkable in vivo therapeutic potential and higher antibiofilm activity against Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2023
- Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategiesBiotechnology Advances, 2019
- Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist InhalerPharmaceutical Research, 2017
- A Clinical Risk Model for the Evaluation of Bronchopleural Fistula in Non-Small Cell Lung Cancer After PneumonectomyThe Annals of Thoracic Surgery, 2013
- Pharmaceutical nanotechnology for oral delivery of anticancer drugsAdvanced Drug Delivery Reviews, 2013
- A Phage Tubulin Assembles Dynamic Filaments by an Atypical Mechanism to Center Viral DNA within the Host CellCell, 2012
- Risk Factor Comparison and Clinical Analysis of Early and Late Bronchopleural Fistula After Non-Small Cell Lung Cancer SurgeryThe Annals of Thoracic Surgery, 2009
- Mechanisms of antimicrobial resistance in bacteriaAmerican Journal of Infection Control, 2006